Acorda Therapeutics, Inc. operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Acorda Therapeutics with three other
companies in this sector in the United States:
sales of $499.02 million
of which 64%
Seattle Genetics, Inc.
of which 100%
was Monoclonal Drugs), and
PDL Biopharma, Inc.
of which 87%
was Income generating assets).
During the year ended December of 2016, sales at
Acorda Therapeutics were $519.60 million.
increase of 5.5%
versus 2015, when the company's sales were $492.66 million.
This was the fifth consecutive year of sales increases at Acorda Therapeutics
(and since 2011, sales have increased a total of 78%).